• Authors: Ji, B., Feng, Y., Sun, Y., Ji, D., Qian, W., Zhang, Z., Wang, Q., Zhang, Y., Zhang, C., Sun, Y.
  • Year: 2018
  • Journal: Oncol Rep 40 1885-1896
  • Applications: in vivo / siRNA / in vivo-jetPEI


The mice with tumor implantation were randomly divided into two groups (NC and siRNA) after 4 weeks. Once every 48 h, an intratumoral injection of si-GPR56 or si-NC mixed with in vivo-jetPEI was performed. After 4 weeks, the nude mice were sacrificed by cervical dislocation and xenograft tumors were dissected.


G proteincoupled receptor 56 (GPR56), a member of the orphan GPCR family, has been reported to be an oncogene in various malignancies. However, little is known regarding the detailed molecular mechanism of GPR56 in colorectal cancer (CRC). The present study aimed to detect the expression level and biological function of GPR56 in CRC. We examined the expression of GPR56 in CRC tissues and cell lines by quantitative real time (qRT)PCR, immunohistochemistry, and western blot analysis. The prognostic significance of GPR56 in CRC patients was evaluated by KaplanMeier survival analysis. The influence of GPR56 on tumor cell proliferation (via Cell Counting Kit8, and a tumor formation assay in mice), apoptosis (flow cytometry), cell cycle distribution (flow cytometry) and migration (Transwell assay) was explored. We also investigated the underlying mechanism of GPR56 by western blot analysis. We found GPR56 expression was significantly upregulated in CRC tissues and cell lines compared to corresponding normal controls. Higher GPR56 expression in patients predicted poorer prognosis. Depletion of GPR56 markedly suppressed cell proliferation, migration, and invasion. GPR56 overexpression promoted CRC cell metastasis by expediting epithelialmesenchymal transition by activating PI3K/AKT signaling. In conclusion, GPR56 played an important role in CRC progression and may represent a new therapeutic target to reduce CRC metastasis.

Go to